Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background & Aims</h3><p>Surgical resection is the primary treatment for hepatocellular carcinoma (HCC); however, it is associated with a high rate of recurrence and death. We conducted this phase II study to investigate the efficacy and safety of postoperative intensity-modulated radiotherapy (IMRT) for HCC after narrow-margin hepatectomy.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Approach & Results</h3><p>We designed a single-arm, prospective phase II trial to evaluate overall survival (OS), disease-free survival (DFS), recurrence patterns, and toxicity in patients receiving adjuvant radiotherapy. The eligibility criteria included the following: pathological diagnosis of HCC after hepatectomy, with narrow pathological margins (<1 cm); age >18 years; and Eastern Cooperative Oncology Group performance status score of 0 or 1. Patients received IMRT within 4–6 weeks after surgical resection. This trial was registered at ClinicalTrials.gov (number: NCT01456156). Between 2008 and 2016, a total of 76 eligible patients who underwent narrow-margin resection were enrolled. The median follow-up duration was 70 months; the 3-year OS and DFS rates were 88.2% and 68.1%, respectively; and the 5-year OS and DFS rates were 72.2% and 51.6%, respectively. Intrahepatic recurrence was the primary recurrence pattern. No marginal recurrence was found. Intrahepatic, extrahepatic, and combined recurrences at the first relapse were found in 33, five, and one patient, respectively. The most common radiation-related grade-3 toxicities were leukopenia (7.9%), elevated alanine aminotransferase (3.9%) and aspartate aminotransferase (2.6%) levels, and thrombocytopenia (1.3%). Classical or non-classical radiation-induced liver disease was not noted.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Adjuvant radiotherapy is an effective, well-tolerated, and promising adjuvant regimen in HCC patients who have undergone narrow-margin hepatectomy. Our trial provides evidence and a rationale for planning a future phase III trial.</p></section>

Survival benefit with IMRT following narrow-margin hepatectomy in patients with hepatocellular carcinoma close to major vessels.

Benefit of adjuvant radiotherapy following narrow-margin hepatectomy in patients with intrahepatic cholangiocarcinoma that adhere to major vessels.

Narrow-Margin Hepatectomy Resulted in Higher Recurrence and Lower Overall Survival for R0 Resection Hepatocellular Carcinoma

Survival benefit of radiotherapy following narrow-margin hepatectomy in patients with hepatocellular carcinoma: A propensity score-matched analysis based on phase II study

Intensity-modulated Radiotherapy Following Null-Margin Resection is Associated with Improved Survival in the Treatment of Intrahepatic Cholangiocarcinoma.

Postoperative Radiotherapy Following Null-Margin Hepatectomy in Patients with Hepatocellular Carcinoma Adhering to the Major Vessels: A Propensity Score-Matched Survival Analysis Cohort Study

Adjuvant radiotherapy after curative resection of hepatocellular carcinoma with narrow margin (≤1 cm): A phase 2, multicenter, randomized controlled trial.

Adjuvant Radiotherapy in Centrally Located Hepatocellular Carcinomas after Hepatectomy with Narrow Margin (<1 Cm): a Prospective Randomized Study.

Phase 2 Study of Adjuvant Radiotherapy Following Narrow‐Margin Hepatectomy in Patients With HCC

Association of Adjuvant Radiotherapy with Long-term Overall and Recurrence-free Survival Following Hepatectomy for Hepatocellular Carcinoma: A Multicenter Propensity-matched Study

Improved survival with radiotherapy in hepatocellular carcinoma with major vascular invasion: A propensity-matched analysis of Surveillance, Epidemiology, and End Results database.

Postoperative Adjuvant Radiotherapy is Associated with Improved Survival in Hepatocellular Carcinoma with Microvascular Invasion

Survival benefit of neoadjuvant hepatic arterial infusion chemotherapy followed by hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus

Exploration of Superior Modality: Safety and Efficacy of Hypofractioned Image-Guided Intensity Modulated Radiation Therapy in Patients with Unresectable but Confined Intrahepatic Hepatocellular Carcinoma

Image-guided Intensity-Modulated Radiotherapy Improves Short-Term Survival for Abdominal Lymph Node Metastases from Hepatocellular Carcinoma.

Long-Term Outcome of Centrally Located Hepatocellular Carcinomas Treated by Radical Resection Combined With Intraoperative Electron Radiotherapy (IOERT)

Efficacy and Safety of Intensity Modulated Radiation Therapy Following Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma

Optimal postoperative adjuvant treatment strategy for HBV-related hepatocellular carcinoma with microvascular invasion: a propensity score analysis.

Adjuvant radiotherapy in central hepatocellular carcinoma after narrow-margin hepatectomy: A 10-year real-world evidence

Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study.

Long-term outcome of adjuvant radiotherapy upon postoperative relapse of centrally located hepatocellular carcinoma: a real-world study